KYTRIL 1MG/1ML LIQUID

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

GRANISETRON (GRANISETRON HYDROCHLORIDE)

Prieinama:

HOFFMANN-LA ROCHE LIMITED

ATC kodas:

A04AA02

INN (Tarptautinis Pavadinimas):

GRANISETRON

Dozė:

1MG

Vaisto forma:

LIQUID

Sudėtis:

GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

1/4ML

Recepto tipas:

Prescription

Gydymo sritis:

5-HT3 RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0123183001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2012-01-06

Prekės savybės

_Page 1 of 32 _
_ _
_ _
PRODUCT MONOGRAPH
Pr KYTRIL
®
Granisetron Hydrochloride Tablets
1 mg & 2 mg granisetron as hydrochloride
Granisetron Hydrochloride Injection
1 mg/mL granisetron as hydrochloride, 1 mL and 4 mL vials
ANTIEMETIC
(5-HT
3 RECEPTOR ANTAGONIST)
Hoffmann-La Roche Limited
Date of Preparation:
2455 Meadowpine Boulevard
2001.02.07
Mississauga, Ontario
L5N 6L7
Date of Revision:
www.rochecanada.com
2009.10.29
CONTROL NO. 129213
® Registered Trade-Mark of F. Hoffmann-La Roche AG used under
license.
© Copyright 2001 – 2009 Hoffmann-La Roche Limited
CDS Version 2.0
_Page 2 of 32 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTRATION..............................................................................10
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND
STABILITY..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHA